Achaogen Inc (NASDAQ:AKAO) major shareholder Robert W. Duggan bought 49,660 shares of the firm’s stock in a transaction on Thursday, March 15th. The stock was bought at an average price of $11.36 per share, with a total value of $564,137.60. Following the completion of the purchase, the insider now owns 6,294,808 shares of the company’s stock, valued at $71,509,018.88. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Achaogen Inc (NASDAQ AKAO) traded up $0.27 on Friday, hitting $11.50. The stock had a trading volume of 1,150,745 shares, compared to its average volume of 855,245. The company has a market capitalization of $502.27, a PE ratio of -3.25 and a beta of 1.28. The company has a debt-to-equity ratio of 0.08, a quick ratio of 4.83 and a current ratio of 4.83. Achaogen Inc has a 52 week low of $9.83 and a 52 week high of $27.49.
Achaogen (NASDAQ:AKAO) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.21). Achaogen had a negative net margin of 1,124.10% and a negative return on equity of 83.14%. The business had revenue of $1.87 million for the quarter, compared to the consensus estimate of $1.18 million. equities analysts forecast that Achaogen Inc will post -3.5 earnings per share for the current fiscal year.
A number of equities analysts have commented on AKAO shares. Guggenheim restated a “buy” rating and issued a $14.00 target price on shares of Achaogen in a research note on Wednesday, January 10th. Zacks Investment Research raised Achaogen from a “sell” rating to a “hold” rating in a report on Monday, December 11th. Needham & Company LLC reaffirmed a “buy” rating and set a $20.00 price target (down previously from $29.00) on shares of Achaogen in a report on Wednesday, February 28th. HC Wainwright lifted their price target on Achaogen from $25.00 to $31.00 and gave the company a “buy” rating in a report on Wednesday, February 7th. Finally, Stifel Nicolaus cut their price target on Achaogen from $27.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, February 28th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $24.10.
TRADEMARK VIOLATION NOTICE: This article was first posted by Week Herald and is the property of of Week Herald. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://weekherald.com/2018/03/17/achaogen-inc-akao-major-shareholder-robert-w-duggan-buys-49660-shares-of-stock.html.
Achaogen, Inc is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE).
Receive News & Ratings for Achaogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achaogen and related companies with MarketBeat.com's FREE daily email newsletter.